About Teleflex (NYSE:TFX)
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease. The company also provides interventional access products that are used in dialysis, oncology, and critical care therapies; and cardiac care products, such as diagnostic and intra-aortic balloon catheters, and capital equipment. In addition, it offers anesthesia products, such as pain management products for use in surgical and obstetric procedures; airway management products and related devices for use in pre-hospital emergency and hospital settings; and other pre-hospital emergency products. Further, the company offers surgical products, including Weck Ligation Systems, Weck EFx Fascial Closure Systems, Percutaneous Surgical Systems, Weck Vista bladeless access ports, Deknatel sutures, and Pilling and Kmedic surgical instruments; products for use in acute care settings for diagnostic and therapeutic procedures, and in general and specialty surgical applications; and single-use respiratory, urology, and interventional urology products. Additionally, it provides devices and instruments for other medical device manufacturers, such as custom-engineered extrusions, diagnostic and interventional catheters, balloon sheath/dilator sets and kits, sutures, performance fibers, and bioresorbable resins and fibers. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was founded in 1943 and is headquartered in Wayne, Pennsylvania.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:TFX
CUSIP87936910
Phone610-225-6800
Debt
Debt-to-Equity Ratio0.89%
Current Ratio2.33%
Quick Ratio1.51%
Price-To-Earnings
Trailing P/E Ratio32.10
Forward P/E Ratio27.91
P/E Growth1.97
Sales & Book Value
Annual Sales$2.15 billion
Price / Sales5.66
Cash Flow$12.3518 per share
Price / Cash21.83
Book Value$53.95 per share
Price / Book5.00
Profitability
EPS (Most Recent Fiscal Year)$8.40
Net Income$152.53 million
Net Margins7.11%
Return on Equity16.46%
Return on Assets6.97%
Miscellaneous
Employees14,400
Outstanding Shares45,050,000
Teleflex (NYSE:TFX) Frequently Asked Questions
What is Teleflex's stock symbol?
Teleflex trades on the New York Stock Exchange (NYSE) under the ticker symbol "TFX."
How often does Teleflex pay dividends? What is the dividend yield for Teleflex?
Teleflex declared a quarterly dividend on Thursday, February 22nd. Stockholders of record on Friday, March 2nd will be paid a dividend of $0.34 per share on Thursday, March 15th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.50%. The ex-dividend date of this dividend is Thursday, March 1st. View Teleflex's Dividend History.
How were Teleflex's earnings last quarter?
Teleflex Incorporated (NYSE:TFX) posted its quarterly earnings data on Thursday, February, 22nd. The medical technology company reported $2.44 EPS for the quarter, beating analysts' consensus estimates of $2.40 by $0.04. The medical technology company had revenue of $595.10 million for the quarter, compared to the consensus estimate of $601.17 million. Teleflex had a net margin of 7.11% and a return on equity of 16.46%. The firm's revenue for the quarter was up 15.8% compared to the same quarter last year. During the same quarter last year, the firm posted $2.13 EPS. View Teleflex's Earnings History.
When is Teleflex's next earnings date?
What guidance has Teleflex issued on next quarter's earnings?
Teleflex updated its FY18 earnings guidance on Thursday, February, 22nd. The company provided earnings per share (EPS) guidance of $9.55-9.75 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $9.64.
What price target have analysts set for TFX?
10 analysts have issued 1 year price targets for Teleflex's stock. Their predictions range from $251.00 to $300.00. On average, they anticipate Teleflex's share price to reach $280.6667 in the next twelve months. View Analyst Ratings for Teleflex.
What are Wall Street analysts saying about Teleflex stock?
Here are some recent quotes from research analysts about Teleflex stock:
- 1. According to Zacks Investment Research, "Teleflex Inc. designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company offers its products to hospitals and healthcare providers through its direct sales force and distributors. Teleflex was founded in 1943 and is headquartered in Wayne, Pennsylvania. " (10/4/2017)
- 2. Barclays analysts commented, "XLRS Progressing Slowly with Some Uncertainty. Although top-line safety data from 12 patients in the Phase I/II XLRS dose escalation study did not reveal SAEs and moderate ocular inflammation was considered manageable, the combination of inter-patient and test variability has affected the ability to determine a therapeutic effect. As a result, AGTC plans to expand enrollment and follow the new patients for at least six months." (9/12/2017)
- 3. Needham & Company LLC analysts commented, "TFX announced it is acquiring NeoTract for $725M of cash upfront and up to another $375M of revenue-based milestone payments. NeoTract has an innovative treatment for benign prostatic hyperplasia (BPH) called UroLift which offers a number of advantages to competing BPH procedures. The BPH market is large and underpenetrated with potential to reach $30B+ worldwide. TFX expects the deal to be accretive to its revenue growth, margins, and EPS by 2019." (9/5/2017)
Who are some of Teleflex's key competitors?
Some companies that are related to Teleflex include ResMed (RMD), Abiomed (ABMD), Dexcom (DXCM), Hill-Rom (HRC), ICU Medical (ICUI), Insulet (PODD), Globus Medical (GMED), Cantel Medical (CMD), Penumbra (PEN), Haemonetics (HAE), Nevro (NVRO), NuVasive (NUVA), Merit Medical Systems (MMSI), NovoCure (NVCR), Mazor Robotics (MZOR), Irhythm Technologies (IRTC), Intersect ENT (XENT) and ATRION (ATRI).
Who are Teleflex's key executives?
Teleflex's management team includes the folowing people:
- Mr. Benson F. Smith, Chairman (Age 70)
- Mr. Liam J. Kelly, Pres & CEO (Age 51)
- Mr. Thomas E. Powell, Exec. VP & CFO (Age 56)
- Mr. James J. Leyden, VP, Gen. Counsel & Sec. (Age 51)
- Mr. Cameron P. Hicks, VP of Global HR (Age 53)
Has Teleflex been receiving favorable news coverage?
News articles about TFX stock have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Teleflex earned a coverage optimism score of 0.09 on Accern's scale. They also assigned press coverage about the medical technology company an impact score of 46.01 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of Teleflex?
Shares of TFX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Teleflex's stock price today?
One share of TFX stock can currently be purchased for approximately $269.64.
How big of a company is Teleflex?
Teleflex has a market capitalization of $12.00 billion and generates $2.15 billion in revenue each year. The medical technology company earns $152.53 million in net income (profit) each year or $8.40 on an earnings per share basis. Teleflex employs 14,400 workers across the globe.
How can I contact Teleflex?
Teleflex's mailing address is 550 E SWEDESFORD RD, WAYNE PA, 19087. The medical technology company can be reached via phone at 610-225-6800 or via email at [email protected]
MarketBeat Community Rating for Teleflex (TFX)
MarketBeat's community ratings are surveys of what our community members think about Teleflex and other stocks. Vote "Outperform" if you believe TFX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TFX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Teleflex (NYSE:TFX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
10 Wall Street analysts have issued ratings and price targets for Teleflex in the last 12 months. Their average twelve-month price target is $280.6667, suggesting that the stock has a possible upside of 4.09%. The high price target for TFX is $300.00 and the low price target for TFX is $251.00. There are currently 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.60 | 2.67 | 2.67 | 2.88 |
| Ratings Breakdown: | 0 Sell Rating(s)
4 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $280.6667 | $283.6250 | $279.3750 | $260.1429 |
| Price Target Upside: | 4.09% upside | 15.29% upside | 2.59% upside | 7.60% upside |
Teleflex (NYSE:TFX) Consensus Price Target History
Teleflex (NYSE:TFX) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
Teleflex (NYSE:TFX) Dividend Information
Teleflex pays an annual dividend of $1.36 per share, with a dividend yield of 0.50%. TFX's most recent quarterly dividend payment was Thursday, March 15. Teleflex pays out 16.19% of its earnings out as a dividend.
| Most Recent Dividend: | 3/15/2018 |
| Annual Dividend: | $1.36 |
| Dividend Yield: | 0.50% |
| Dividend Growth: | 0.00% (3 Year Average) |
| Payout Ratio: | 16.19% (Trailing 12 Months of Earnings)
14.08% (Based on This Year's Estimates)
11.96% (Based on Next Year's Estimates)
|
| Frequency: | Quarterly Dividend |
Teleflex (NYSE:TFX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 2/22/2018 | quarterly | $0.34 | 0.53% | 3/1/2018 | 3/2/2018 | 3/15/2018 |
| 11/2/2017 | quarterly | $0.34 | 0.53% | 11/14/2017 | 11/15/2017 | 12/15/2017 |
| 8/3/2017 | quarterly | $0.34 | 0.63% | 8/11/2017 | 8/15/2017 | 9/15/2017 |
| 5/8/2017 | quarterly | $0.34 | 0.7% | 5/11/2017 | 5/15/2017 | 6/15/2017 |
| 2/23/2017 | quarterly | $0.34 | | 3/1/2017 | 3/3/2017 | 3/15/2017 |
| 10/27/2016 | quarterly | $0.34 | 0.98% | 11/10/2016 | 11/15/2016 | 12/15/2016 |
| 7/28/2016 | quarterly | $0.34 | 0.75% | 8/11/2016 | 8/15/2016 | 9/15/2016 |
| 5/2/2016 | quarterly | $0.34 | | 5/12/2016 | 5/16/2016 | 6/15/2016 |
| 2/25/2016 | quarterly | $0.34 | 0.94% | 3/2/2016 | 3/4/2016 | 3/15/2016 |
| 10/29/2015 | quarterly | $0.34 | 1.02% | 11/10/2015 | 11/13/2015 | 12/14/2015 |
| 7/30/2015 | quarterly | $0.34 | 1.02% | 8/12/2015 | 8/14/2015 | 9/14/2015 |
| 5/4/2015 | quarterly | $0.34 | 1.09% | 5/12/2015 | 5/14/2015 | 6/15/2015 |
| 2/20/2015 | quarterly | $0.34 | 1.13% | 2/27/2015 | 3/3/2015 | 3/16/2015 |
| 10/29/2014 | quarterly | $0.34 | | 11/12/2014 | 11/14/2014 | 12/15/2014 |
| 7/30/2014 | quarterly | $0.34 | 1.25% | 8/13/2014 | 8/15/2014 | 9/15/2014 |
| 5/5/2014 | quarterly | $0.34 | 1.31% | 5/13/2014 | 5/15/2014 | 6/16/2014 |
| 2/21/2014 | quarterly | $0.34 | 1.34% | 2/28/2014 | 3/4/2014 | 3/14/2014 |
| 10/30/2013 | quarterly | $0.34 | 1.49% | 11/13/2013 | 11/15/2013 | 12/13/2013 |
| 7/31/2013 | quarterly | $0.34 | 1.72% | 8/13/2013 | 8/15/2013 | 9/13/2013 |
| 5/3/2013 | quarterly | $0.34 | 1.75% | 5/13/2013 | 5/15/2013 | 6/14/2013 |
| 2/21/2013 | quarterly | $0.34 | 1.74% | 3/1/2013 | 3/5/2013 | 3/15/2013 |
(Data available from 1/1/2013 forward)
Teleflex (NYSE TFX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 2.56%
Institutional Ownership Percentage: 90.90%
Teleflex (NYSE TFX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/16/2018 | Benson Smith | Director | Sell | 9,331 | $260.52 | $2,430,912.12 | 77,498 |  |
| 4/9/2018 | George Babich Jr | Director | Sell | 2,500 | $246.87 | $617,175.00 | 11,083 | |
| 4/2/2018 | Benson Smith | Director | Sell | 9,331 | $251.49 | $2,346,653.19 | 83,711 | |
| 3/26/2018 | George Babich Jr | Director | Sell | 2,500 | $254.53 | $636,325.00 | 8,794 | |
| 3/12/2018 | George Babich Jr | Director | Sell | 2,500 | $268.53 | $671,325.00 | 11,083 | |
| 2/28/2018 | John Deren | VP | Sell | 1,359 | $255.67 | $347,455.53 | | |
| 2/26/2018 | George Babich Jr | Director | Sell | 2,500 | $255.61 | $639,025.00 | 8,886 | |
| 2/12/2018 | George Babich Jr | Director | Sell | 2,500 | $252.57 | $631,425.00 | 10,259 | |
| 2/1/2018 | Stephen K M.D. Klasko | Director | Sell | 200 | $276.44 | $55,288.00 | 8,080 | |
| 1/29/2018 | George Babich Jr | Director | Sell | 2,500 | $283.11 | $707,775.00 | 9,581 | |
| 1/16/2018 | George Babich Jr | Director | Sell | 2,500 | $263.38 | $658,450.00 | 10,583 | |
| 1/2/2018 | Stephen K M.D. Klasko | Director | Sell | 200 | $248.96 | $49,792.00 | 8,080 | |
| 12/4/2017 | Benson Smith | CEO | Sell | 2,000 | $258.10 | $516,200.00 | 76,634 | |
| 12/1/2017 | Stephen K M.D. Klasko | Director | Sell | 200 | $265.32 | $53,064.00 | 8,080 | |
| 11/1/2017 | Stephen K M.D. Klasko | Director | Sell | 200 | $237.18 | $47,436.00 | 8,080 | |
| 10/2/2017 | Stephen K M.D. Klasko | Director | Sell | 200 | $241.88 | $48,376.00 | 8,080 | |
| 9/1/2017 | Stephen K M.D. Klasko | Director | Sell | 200 | $211.75 | $42,350.00 | 8,080 | |
| 8/1/2017 | Stephen K M.D. Klasko | Director | Sell | 200 | $208.41 | $41,682.00 | 8,080 | |
| 7/3/2017 | Stephen K M.D. Klasko | Director | Sell | 200 | $208.10 | $41,620.00 | 8,080 | |
| 6/21/2017 | Gretchen R Haggerty | Director | Buy | 1,000 | $203.82 | $203,820.00 | 1,760 | |
| 6/7/2017 | Stuart A Randle | Director | Sell | 2,500 | $205.67 | $514,175.00 | 7,532 | |
| 6/1/2017 | Stephen K M.D. Klasko | Director | Sell | 200 | $199.93 | $39,986.00 | 8,080 | |
| 5/15/2017 | Stephen K M.D. Klasko | Director | Sell | 5,200 | $193.56 | $1,006,512.00 | 12,880 | |
| 5/9/2017 | John Deren | VP | Sell | 2,246 | $194.07 | $435,881.22 | 3,989 | |
| 12/21/2016 | Jeffrey A Graves | Director | Sell | 5,000 | $160.57 | $802,850.00 | 13,022 | |
| 6/6/2016 | Stuart A Randle | Director | Sell | 797 | $166.10 | $132,381.70 | 4,592 | |
| 5/16/2016 | Thomas Anthony Kennedy | VP | Sell | 15,102 | $160.20 | $2,419,340.40 | 6,990 | |
| 8/20/2015 | Patricia C Barron | Director | Sell | 1,500 | $132.74 | $199,110.00 | 7,623 | |
| 12/22/2014 | Liam Kelly | EVP | Sell | 3,360 | $117.38 | $394,396.80 | | |
| 12/1/2014 | George Babich Jr | Director | Sell | 5,000 | $118.20 | $591,000.00 | | |
| 9/5/2013 | William Roland Cook | Director | Sell | 2,696 | $77.32 | $208,454.72 | | |
| 8/8/2013 | Patricia Barron | Director | Sell | 4,000 | $77.66 | $310,640.00 | 5,677 | |
(Data available from 1/1/2013 forward)
Teleflex (NYSE TFX) News Headlines
| Source: |
|
Teleflex (NYSE:TFX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Teleflex (NYSE:TFX) Income Statement, Balance Sheet and Cash Flow Statement
Teleflex (NYSE TFX) Stock Chart for Friday, April, 20, 2018
Loading chart…
